Last updated: July 6, 2026
Bayer Healthcare LLC v. Apotex, Inc. (1:16-cv-01222): Litigation Summary, Timeline, Claims, and Generic-Entry Implications
Bayer Healthcare LLC v. Apotex, Inc., No. 1:16-cv-01222 (D. Del.), is a US Hatch-Waxman patent infringement case tied to a branded Bayer product with an Apotex generic challenge. The docket reflects an ANDA-related dispute in which Bayer asserted one or more Orange Book-listed patents and Apotex responded with invalidity/non-infringement positions typical of Paragraph IV litigation. The litigation history and procedural posture determine the practical “launch window” risk for Apotex and peers and frame how courts treated claim construction, infringement theories, and obviousness/anticipation defenses.
Case caption: Bayer Healthcare LLC v. Apotex, Inc.
Court: US District Court for the District of Delaware
Case number: 1:16-cv-01222
What patents were asserted in Bayer Healthcare LLC v. Apotex, Inc. | 1:16-cv-01222?
The information necessary to produce a complete, accurate patent-assertion map for this specific docket is not present in the provided record. A litigation summary that names asserted patents, publication numbers, claim numbers, and then ties those elements to specific infringement/invalidity positions requires docket-level detail (complaint, amended complaints, and the infringement contentions). Without that, any patent list would be incomplete or potentially wrong, which prevents a correct analysis.
Which Orange Book-listed patents typically appear in these Bayer v. Apotex ANDA cases?
In Bayer ANDA disputes, the asserted portfolio is commonly split across:
- Composition-of-matter or drug substance patents
- Formulation patents (solid state, polymorphs, particle size, coatings)
- Method-of-use patents
- Device/administration patents (when relevant)
- Manufacturing process patents (sometimes tied to specific intermediate/control steps)
This case may include any subset of the above, but the asserted list cannot be derived from the case number alone.
When was the case filed and what were the key procedural events in 1:16-cv-01222?
A litigation timeline requires docket events such as:
- complaint filing date
- answer and defenses
- scheduling order
- Markman hearing date
- claim construction order date
- summary judgment rulings
- trial dates (if any)
- final judgment date
- post-trial motions and appeals (if any)
No such event dates were supplied. Without them, an accurate timeline cannot be produced.
What procedural posture usually drives the commercial “generic launch” impact?
For Hatch-Waxman cases, commercial impact is usually tied to:
- teed-up injunction risk after claim construction
- early dispositive motions (dismissal, venue, indirect infringement theories)
- summary judgment resolving infringement or validity
- final judgment determining whether the ANDA can launch before patent expiry
This case’s actual posture must be read from the docket entries and orders.
How did the court treat claim construction in Bayer Healthcare LLC v. Apotex, Inc.?
Claim construction outcomes often decide the case because they control whether Apotex’s ANDA product falls within claim scope, especially in formulation and method-of-use patents.
However, a claim-construction analysis requires:
- the specific disputed claim terms
- the court’s construction
- whether constructions favored Bayer or Apotex
- how those constructions mapped onto the accused product characterization and Bayer’s validity theories
Those details are not available in the provided record.
What infringement theories typically appear when Bayer sues Apotex in ANDA cases?
In these cases, infringement theories commonly include:
- literal infringement of composition/formulation parameters
- infringement via equivalents (for range limitations)
- method-of-use inducement or direct infringement depending on carve-outs
- challenge to Apotex’s label or submitted formulation data
The exact theories in 1:16-cv-01222 cannot be verified without the pleadings and infringement contentions.
What invalidity defenses did Apotex raise in 1:16-cv-01222 (obviousness, anticipation, enablement)?
An invalidity analysis must be anchored to the defenses actually pleaded and pursued, including:
- prior art references asserted
- legal theories (35 USC 102/103/112)
- priority and claim scope issues
- the existence of secondary considerations
- whether the court resolved invalidity at summary judgment or trial
None of those elements are available from the provided input.
Which patent invalidity issues most often decide Bayer vs. generic cases in Delaware?
Common Delaware outcomes include:
- anticipation of formulation parameters by specific prior art disclosures
- obviousness where ranges overlap and a motivation to combine is found
- written description/enablement challenges for claimed solids, polymorphs, or process steps
This case’s actual results cannot be stated accurately.
Did Apotex file a Paragraph IV certification, and what was the launch/exclusivity risk in 2016?
Paragraph IV implications depend on:
- the ANDA approval date and tentative approval
- the Orange Book patent list tied to the certification
- the certification date (which triggers the 45-day clock)
- whether any 30-month stay applied and when it ended
- any settlement leading to a “launch-forbidden” or “carve-out” date
Those facts are not present in the provided record, so the Paragraph IV timing and launch risk cannot be stated without risking inaccuracy.
What is the Orange Book status of the underlying Bayer product involved in 1:16-cv-01222?
Orange Book status requires:
- identification of the approved drug (brand and generic name)
- the Orange Book patent list (US patents and expiration dates)
- exclusivity type (NCE, pediatric, new clinical investigation, orphan drug)
- which patents were litigated
The case number alone does not uniquely determine the product or the Orange Book patent list.
How strong is Bayer’s patent estate in this dispute versus Apotex’s generic risk?
A strength assessment requires:
- the asserted patent claim breadth
- claim construction results
- whether validity was challenged with the same art already considered in prosecution
- the court’s final infringement/validity findings
Without the asserted patents and the court’s rulings, any “strength” rating would be unsupported.
What did Bayer ask for (injunction, damages) and what did the court award?
A complete litigation summary needs:
- the requested remedies (injunction under 35 USC 283, damages under 35 USC 284)
- the final disposition (win/loss, invalidation, injunction scope)
- damages period and any stay pending appeal
Those outcomes are not provided.
Key Takeaways
- Bayer v. Apotex, No. 1:16-cv-01222 (D. Del.), is an ANDA-related patent infringement dispute, but the provided record does not include the asserted patent list, claim constructions, validity/infringement rulings, or final judgment.
- A litigation-ready analysis that supports licensing, generic-entry timing, or investment decisions requires docket-level facts (complaint, amended pleadings, Markman order, summary judgment/final judgment, and any settlement or consent to judgment entries). Those facts are not included here.
FAQs
- Which patents did Bayer assert against Apotex in 1:16-cv-01222?
- What claim terms and constructions did the court adopt in Bayer v. Apotex (1:16-cv-01222)?
- Did the case end in summary judgment or trial, and what was the final disposition?
- What Paragraph IV certification and 30-month stay events drove the litigation timing in 1:16-cv-01222?
- Did the parties reach a settlement, and what launch/entry date was set by any agreement?
References
- US District Court for the District of Delaware. Bayer Healthcare LLC v. Apotex, Inc., No. 1:16-cv-01222.
